May 9 |
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials
|
May 9 |
RAPT Therapeutics plunges 40% as it ends phase 2 study of lead asset zelnecirnon
|
May 9 |
RAPT Therapeutics GAAP EPS of -$0.79
|
May 9 |
RAPT Therapeutics Reports First Quarter 2024 Financial Results
|
Apr 9 |
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
|
Apr 9 |
3 Biotech Stocks to Dump Before They Go to Zero
|
Mar 22 |
What Makes RAPT Therapeutics (RAPT) an Investment Choice?
|
Mar 7 |
RAPT Therapeutics GAAP EPS of -$0.80
|
Mar 7 |
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
|
Mar 7 |
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
|